Literature DB >> 12163054

Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines.

Doriane Richard1, Hamid Morjani, Benoît Chénais.   

Abstract

Aclarubicin (ACLA), which belongs to the antracycline class of antineoplasic agents, has been demonstrated as a differentiating agent for a broad range of human solid tumors and leukemia. By using dihydroethidium as a fluorescent probe, we show the ability of subtoxic (i.e. differentiating) concentration of ACLA to generate reactive oxygen species in both K562 and HL-60 leukemia cell lines. Besides, we have used a calcein-based spectrofluorimetric assay to determine the influence of ACLA treatment on the cellular labile iron pool (LIP). In both cell lines, the LIP level was markedly decreased in the presence of ACLA. Nevertheless, whereas ACLA-induced differentiation was obviously ROS-dependent, the LIP decrease was rather ROS-independent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163054     DOI: 10.1016/s0145-2126(02)00030-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

Review 1.  Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth.

Authors:  Jacek Zielonka; B Kalyanaraman
Journal:  Free Radic Biol Med       Date:  2010-01-29       Impact factor: 7.376

Review 2.  Air pollutants disrupt iron homeostasis to impact oxidant generation, biological effects, and tissue injury.

Authors:  Andrew J Ghio; Joleen M Soukup; Lisa A Dailey; Michael C Madden
Journal:  Free Radic Biol Med       Date:  2020-02-21       Impact factor: 7.376

3.  Gan-Lu-Yin Inhibits Proliferation and Migration of Murine WEHI-3 Leukemia Cells and Tumor Growth in BALB/C Allograft Tumor Model.

Authors:  Fon-Chang Liu; Chun-Hsu Pan; Ming-Tsung Lai; Shu-Jen Chang; Jing-Gung Chung; Chieh-Hsi Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-17       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.